SCHEMBL2912882

SCHEMBL2912882

CC(=O)Nc1ccc(C)c(-c2ccc(C(=O)O)cc2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 11/20 0.62
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.49
HTT P42858 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
MAPK13 O15264 1/20 0.48
BRAF P15056 1/20 0.48
KDR P35968 1/20 0.48
MAPK12 P53778 1/20 0.48
MAPK11 Q15759 1/20 0.48
KDM5A P29375 1/20 0.48
KDM4D Q6B0I6 1/20 0.48
KDM4C Q9H3R0 1/20 0.48
KDM5B Q9UGL1 1/20 0.48
KDM3A Q9Y4C1 1/20 0.48
ABL1 P00519 1/20 0.46
MEN1 O00255 2/20 0.45
ALDH1A1 P00352 2/20 0.45
MAPT P10636 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2912590 0.88 MAPK14 (0.50) MAPK14CYP1A2CYP3A4MAPK13BRAF
SCHEMBL4436251 0.88 CYP1A2 (0.52) MAPK14CYP1A2CYP3A4SMN1; SMN2HTT
SCHEMBL29131169 0.86 TDP1 (0.61) MAPK14SMN1; SMN2HTTL3MBTL1MAPK13
SCHEMBL29131177 0.86 KMT2A (0.57) MAPK14SMN1; SMN2MAPK13BRAFKDR
SCHEMBL2912653 0.84 IP6K1 (0.49) MAPK14SMN1; SMN2HTTL3MBTL1MEN1
SCHEMBL2348556 0.84 MAPK14 (0.67) MAPK14CYP1A2CYP3A4SMN1; SMN2MAPK13
SCHEMBL2913670 0.84 MEN1 (0.53) MAPK14L3MBTL1MEN1MAPTKMT2A
SCHEMBL2914638 0.82 MITF (0.64) MAPK14SMN1; SMN2HTTABL1MEN1
SCHEMBL2914161 0.82 MAPK14 (0.67) MAPK14CYP1A2ALDH1A1MAPTKDM4E
SCHEMBL2349750 0.82 MAPK14 (0.69) MAPK14ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940786-B1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C ARROW THERAPEUTICS LTD (GB) 2010-08-18 EP disclosed
US-20080255105-A1 Biphenyl Derivatives and Their Use in Treating Hepatitis C ARROW THERAPEUTICS LIMITED (GB) 2008-10-16 US disclosed
EP-1940786-A1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C Arrow Therapeutics Limited (GB) 2008-07-09 EP disclosed
WO-2007031791-A1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C ARROW THERAPEUTICS LIMITED (GB) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255105-A1 Biphenyl Derivatives and Their Use in Treating Hepatitis C NR4A1, NR0B1, NR1H4 MAPK14 4315/4885CYP1A2 126/4885CYP3A4 71/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.